Q&A – Clinical trials
2cureX is happy to receive a number of questions and comments from our present and from potential future shareholders.
With the present Questions & Answers (Q&A) section, we would like to make these questions and their answers publicly available. Additional questions/comments should be mailed to info@2cureX.com.
Posted on 2020-10-04
It is expected that the final clinical data of the TICC1 trial will be published in Q1 2021. It is correct as the Principal Investigator Lars Henrik Jensen stated in the press release that the patients will go through a follow-up examination eight weeks after the IndiTreat-guided treatment is started. At the follow-up the effect of the treatment is evaluated by CT scanning. Thereafter data from all patients will need to be assembled, evaluated and published. We expect this finalized in the first quarter of 2021.
Posted on 2018-03-20
Yes, the first patients were enrolled end of October 2017. In February 2018 we had successfully enrolled the first 10 patients.
Please contact 2cureX for more information
December 7, 2021
CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)
December 9, 2021
2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)
January 20, 2022
2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)
February 24, 2022
Year-End Report 2021